Filing summary
Issuer mismatch: The supplied filing is AmpliPhi Biosciences Corporation’s Form 10-Q, not a filing under the name Armata Pharmaceuticals, Inc. It covers the quarter ended September 30, 2015; confirm the issuer and filing before relying on this summary.
Business context and reporting period
AmpliPhi was a development-stage biotechnology company developing bacteriophage therapies. Its lead candidates targeted P. aeruginosa lung infections (AB-PA01), S. aureus infections (AB-SA01), and C. difficile infections (AB-CD01). The unaudited filing reports the three and nine months ended September 30, 2015, with comparisons to 2014.
Financial results and liquidity
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $143,000 | $103,000 | $347,000 | $308,000 |
| Research and development | $728,000 | $1.793 million | $2.777 million | $4.692 million |
| General and administrative | $1.554 million | $1.701 million | $4.568 million | $5.289 million |
| Operating loss | $2.428 million | $5.231 million | $7.287 million | $11.513 million |
| Net income | $5.439 million | $21.207 million | $1.715 million | $23.773 million |
| Net income (loss) attributable to common stockholders | $(1.724) million | $20.884 million | $(7.614) million | $22.818 million |
| Operating cash flow | Not separately presented | Not separately presented | $(7.464) million | $(9.372) million |
Revenue came from sublicensing agreements related to the former gene therapy program, not product sales. Net income included non-cash gains from remeasuring warrant and Series B preferred-stock derivative liabilities: $7.738 million combined in Q3 2015 and $9.304 million for the first nine months. Preferred-stock dividend accretion made the nine-month common-stockholder result a loss despite reported net income. Operating margins were negative; a gross margin is not clearly provided.
Cash and cash equivalents were $11.737 million at September 30, 2015, up from $6.581 million at December 31, 2014. Current assets were $12.562 million and current liabilities $2.259 million. The filing reports no debt balance. Financing activities provided $12.780 million in the first nine months, principally from the March private placement; investing used $160,000. Total liabilities were $7.474 million. Series B redeemable convertible preferred stock had a $13.068 million liquidation preference and accrued dividends; it is not presented as conventional debt.
Material changes versus prior comparable periods
- Revenue increased modestly, while operating expenses fell: nine-month R&D declined $1.915 million and G&A declined $721,000. Management attributed lower R&D mainly to reduced non-clinical spending, prior-year facility start-up costs, and Australian research grants; lower G&A reflected prior-year CEO departure and shareholder-related costs.
- Reported net income fell sharply year over year, primarily because fair-value gains on preferred derivatives and warrants were substantially smaller than in 2014. The 2015 nine-month gain on these liabilities totaled $9.304 million versus $35.286 million in 2014.
- In March 2015, the company raised approximately $13.0 million gross through a common-stock and warrant private placement, receiving about $12.4 million net. Common shares outstanding rose to 5,883,503 by September 30, from 3,983,182 at year-end 2014.
- A 1-for-50 reverse stock split took effect August 7, 2015; the company also increased authorized common shares to 670 million. Amendments and the share authorization change allowed reclassification of most warrant liabilities to equity.
Outlook, commentary, risks, and unusual items
- Management said available resources were expected to fund planned operations through the third quarter of 2016. It also stated that additional funding would be required; no assurance was given that financing would be available on acceptable terms. Failure to obtain funding could force delays, reductions, or cessation of development programs.
- Management expected R&D spending to increase as studies, hiring, clinical-trial preparation, and discovery work progressed. The company did not expect product revenue in the near term and anticipated continuing operating losses.
- Key risks include early-stage product development, uncertain clinical and regulatory outcomes, formulation and manufacturing scale-up, dependence on collaborators and third parties, limited cash runway, potential dilution, and accrued Series B dividends. Phage therapies had not received regulatory approval, and the filing noted uncertainty around clinical timing and manufacturing readiness.
- Series B preferred stock accrues cumulative dividends at 10% annually. The filing reports $368,000 of dividends payable as a current liability and separately describes approximately $2.9 million of aggregate accrued but unpaid Series B dividends; verify the differing figures and their scope. Holders may have redemption rights beginning in 2018, subject to stated conditions.
- The company recorded a $289,000 severance charge in Q3 2015 related to an executive departure. A September 2015 Takara Bio license generated a $40,000 upfront payment, with royalties and potential milestones. After quarter-end, AmpliPhi signed an agreement for an investigator-initiated Phase 1 AB-SA01 study at the University of Adelaide.
- Management said disclosure controls were effective at a reasonable assurance level and reported no material quarterly change in internal control over financial reporting. However, the filing describes a prior material weakness involving complex and non-routine transactions, restated prior financial statements, and continuing remediation efforts.
Most important facts to verify
- Confirm that this AmpliPhi 2015 filing is the intended issuer and period, given the request names Armata Pharmaceuticals.
- Assess the cash runway assumptions and the timing, amount, and terms of anticipated financing needs.
- Separate recurring operating performance from non-cash fair-value gains and preferred-stock accretion when evaluating earnings.
- Reconcile accrued Series B dividends, including the $368,000 payable balance and the separately stated approximately $2.9 million accrued amount, and review redemption and dilution terms.
- Check subsequent progress on the AB-SA01 clinical study, manufacturing readiness, and remediation of the prior internal-control weakness.